AbbVie Presents Preliminary Results From Phase I Study of Investigational Oncology Compound...
23 hrs ago | checkorphan.org
AbbVie announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL),...
Read more...
GDC-0199 ABT-199 CLL AbbVie patient dose BCL-2 preliminary TLS oncology 17p AEs response MCL